<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32123048</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e697</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000697</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To investigate inflammatory cytokines in patients with motor neuron disease (MND) evaluating the putative contribution of amyotrophic lateral sclerosis (ALS)-causing gene variants.</AbstractText><AbstractText Label="METHODS">This study is a retrospective case series with prospective follow-up (1994-2016) of 248 patients with MND, of whom 164 had ALS who were screened for mutations in the genes for <i>SOD1</i> and <i>C9orf72</i>. Paired CSF and plasma were collected at the diagnostic evaluation before treatment. A panel of cytokines were measured blindly via digital ELISA on the Simoa platform.</AbstractText><AbstractText Label="RESULTS">Time from disease onset to death was longer for patients with ALS-causing <i>SOD1</i> mutations (mSOD1, n = 24) than those with <i>C9orf72</i> hexanucleotide repeat expansion (C9orf72HRE) ALS (n = 19; <i>q</i> = 0.001) and other ALS (OALS) (n = 119; <i>q</i> = 0.0008). Patients with OALS had higher CSF tumor necrosis factor alpha (TNF-&#x3b1;) compared with those with C9orf72HRE ALS (<i>q</i> = 0.014). Patients with C9orf72HRE ALS had higher CSF interferon alpha compared with those with OALS and mSOD1 ALS (<i>q</i> = 0.042 and <i>q</i> = 0.042). In patients with ALS, the survival was negatively correlated with plasma interleukin (IL) 10 (hazard ratio [HR] 1.17, 95% CI 1.05-1.30). Plasma TNF-&#x3b1;, IL-10, and TNF-related apoptosis-inducing ligand (TRAIL) (HR 1.01 [1.00-1.02], 1.15 [1.02-1.30], and 1.01 [1.00-1.01], respectively) of patients with OALS, plasma IL-1&#x3b2; (HR 5.90 [1.27-27.5]) of patients with C9orf72HRE ALS, and CSF TRAIL (10.5 [1.12-98.6]) of patients with mSOD1 ALS all correlated negatively with survival.</AbstractText><AbstractText Label="CONCLUSIONS">Differences in survival times in ALS subtypes were correlated with cytokine levels, suggesting specific immune responses related to ALS genetic variants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olesen</LastName><ForeName>Mads Nikolaj</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuolikainen</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Anna Christine</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirenfeldt</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Jonna Skov</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lillevang</LastName><ForeName>Soeren Thue</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandslund</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter Munch</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asgari</LastName><ForeName>Nasrin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Institutes of Regional Health Research and Molecular Medicine (M.N.O., N.A.), University of Southern Denmark; Departments of Neurology (M.N.O.), Slagelse Hospital &amp; Biochemistry &amp; Immunology, Lillebaelt Hospital, Vejle, Denmark; Department of Pharmacology and Clinical Neuroscience (A.W., K.F., P.M.A.), Ume&#xe5; University, Sweden; Department of Clinical Immunology (A.C.N., S.T.L.), Odense University Hospital, Denmark; Department of Pathology (M.W.), Odense University Hospital, Denmark; Biochemistry &amp; Immunology (J.S.M., I.B.), Lillebaelt Hospital, Vejle, Denmark; Institute of Regional Health Research (J.S.M., I.B.), University of Southern Denmark, Odense; Department of Neurology (N.A.), Slagelse Hospital; and OPEN, Odense Patient Data Explorative Network (N.A.), Odense University Hospital, Denmark. nasgari@health.sdu.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32123048</ArticleId><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId><ArticleId IdType="pii">7/3/e697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(suppl 1):S3&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017;88:540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens T, Khorooshi R, Wlodarczyk A, Asgari N. Interferons in the central nervous system: a few instruments play many tunes. Glia 2014;62:339&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">24588027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Yang B, Zhang D. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia 2011;59:946&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Ona VO, Gu&#xe9;gan C, et al. . Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Lo Coco D, Veglianese P, et al. . Amyotrophic lateral sclerosis, a multisystem pathology: insights into the role of TNFalpha. Mediators Inflamm 2017;2017:2985051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610855</ArticleId><ArticleId IdType="pubmed">29081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, et al. . EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2014;revised report of an EFNS task force. Eur J Neurol 2012;19:360&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. . A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin I, Birve A, Berdynski M, et al. . Comprehensive analysis to explain reduced or increased SOD1 enzymatic activity in ALS patients and their relatives. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">28325066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DH, Rissin DM, Kan CW, et al. . The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom 2016;21:533&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">26077162</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Forsgren L, Binzer M, et al. . Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation: a clinical and genealogical study of 36 patients. Brain 1996;119:1153&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 2017;11:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343070</ArticleId><ArticleId IdType="pubmed">28337127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sta M, Sylva-Steenland RMR, Casula M, et al. . Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 2011;42:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220013</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S, Atkin JD. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res 2016;1648:633&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">27064076</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 2017;10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Yamanaka K, Lobsiger CS, et al. . Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004;22:929&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">15032600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wang L, Chi PD, et al. . High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. Br J Cancer 2016;114:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815778</ArticleId><ArticleId IdType="pubmed">26882069</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Liu W, Wang X, Wang X, Sun H. Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett 2019;17:2365&#x2013;2369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350276</ArticleId><ArticleId IdType="pubmed">30719112</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013;70:1505&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">24145899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation 2016;13:297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5121946</ArticleId><ArticleId IdType="pubmed">27881137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011;91:461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Berjaoui S, Povedano M, Garcia-Esparcia P, Carmona M, Aso E, Ferrer I. Complex inflammation mRNA-related response in ALS is region dependent. Neural Plast 2015;2015:573784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537753</ArticleId><ArticleId IdType="pubmed">26301107</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon GS, Shim YM, Lee DY, et al. . Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol Neurobiol 2019;56:2007&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Fagegaltier D, Agius P, et al. . Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. Elife 2018;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6103746</ArticleId><ArticleId IdType="pubmed">30003873</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, et al. . Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 2016;8:347ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013;125:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun 2018;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, et al. . TDP-43 activates microglia through NF-kappaB and NLRP3 inflammasome. Exp Neurol 2015;273:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z, Liu L, Tao Z, et al. . Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat Commun 2019;10:2906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med 2019;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554670</ArticleId><ArticleId IdType="pubmed">31015277</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. . Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez S, Schrank BR, Sahin A, et al. . Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, provoke propagated neuronal death. bioRxiv 2018:248328.</Citation></Reference><Reference><Citation>Jiang YM, Yamamoto M, Tanaka F, et al. . Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007;66:617&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620987</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos G, Llado J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm 2014;2014:861231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055424</ArticleId><ArticleId IdType="pubmed">24966471</ArticleId></ArticleIdList></Reference><Reference><Citation>Poloni M, Facchetti D, Mai R, et al. . Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 2000;287:211&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10863032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonar S, Lal G. Role of tumor necrosis factor superfamily in neuroinflammation and autoimmunity. Front Immunol 2015;6:364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507150</ArticleId><ArticleId IdType="pubmed">26257732</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Munsat TL, Kao KP, et al. . Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis. Neurology 1986;36:1137&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">3526180</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Aksamit AJ, Madden DL, Sever JL. Administration of recombinant human leukocyte alpha 2-interferon in patients with amyotrophic lateral sclerosis. Arch Neurol 1986;43:933&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">3741210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 1994;51:861&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080385</ArticleId></ArticleIdList></Reference><Reference><Citation>Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 1996;243:117&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">8750546</ArticleId></ArticleIdList></Reference><Reference><Citation>Stommel EW, Cohen JA, Fadul CE, et al. . Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler 2009;10:393&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820489</ArticleId><ArticleId IdType="pubmed">19922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam L, Halder RC, Montoya DJ, et al. . Anti-inflammatory therapies of amyotrophic lateral sclerosis guided by immune pathways. Am J Neurodegener Dis 2015;4:28&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4700124</ArticleId><ArticleId IdType="pubmed">26807342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kothur K, Wienholt L, Brilot F, Dale RC`. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. Cytokine 2016;77:227&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">26463515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>